1 result
  • erbitux

    (cetuximab)
    ImClone LLC
    ERBITUX is indicated for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck (SCCHN), recurrent or metastatic SCCHN, K-Ras wild-type metastatic colorectal cancer (mCRC), and BRAF V600E mutation-positive mCRC in combination with specific therapies. It is not for Ras-mutant cancers.